Key facts
- It has raised $540K; the latest was Later Stage VC ($140K) in Jun 2025.
- Notable investors include National Institutes of Health, Matter (Consulting Services (B2B)), Lung, NIH Seed, National Heart — 8 tracked in total.
- Inomagen Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Jun 2025 ($140K sold to 4 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Inomagen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Inomagen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inomagen Therapeutics
Developer of a non-viral gene therapy designed to treat the underlying mechanisms of atrial fibrillation. The company offers a proprietary gene delivery system utilising reversible electroporation for targeted, minimally invasive transvenous administration of genetic material to the cardiac atrium, enabling patients to get treatment with various stages of atrial fibrillation by addressing molecular causes and reducing arrhythmia and fibrosis, thus providing an alternative to existing therapies that do not target disease origins.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2014
- Employees
- 5
- Website
- inomagen.com/
- Ownership
- Privately Held (backing)
Inomagen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inomagen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inomagen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.